Dongguk University, Jung-gu, Seoul, Republic of Korea.
Dongguk University Ilsan Oriental Hospital, Goyang-si, Gyeonggi-do, Republic of Korea.
Integr Cancer Ther. 2024 Jan-Dec;23:15347354231226115. doi: 10.1177/15347354231226115.
Chemotherapy-induced leukopenia is a common side effect of cytotoxic anticancer drugs. It can deprive patients of treatment opportunities, resulting in the delay, reduction, or discontinuation of chemotherapy or other anticancer drug administration. Two researchers searched English, Chinese, Japanese, and Korean electronic databases, without limiting the time period and language, using search terms such as "Bojungikgi," "WBC," "leuko," and "neutrop." Among the human randomized controlled studies in which Bojungikgi-tang was administered to patients who underwent chemotherapy, studies reporting leukopenia-related outcomes were selected, and data extraction, bias risk assessment, and meta-analysis were performed on the selected papers. Ten studies were selected, and a systematic review with meta-analysis was conducted. Nine papers were published in China and the total number of participants was 715. As a result of administering Bojungikgi-tang to these patients, the number of patients with chemotherapy-induced leukopenia significantly decreased (OR: 0.41, 95% CI: 0.27-0.61, = .0001, = 35%). Further, white blood cell counts were compared with that of the control group, and it showed an effect on prevention (MD: 0.64, 95% CI: 0.46-0.83, < .00001, = 90%). A pronounced effect was observed, especially when administered after a diagnosis based on the pattern identification, such as Qi deficiency. (OR: 0.32, 95% CI: 0.18-0.58, = .0002, = 0%). However, all studies had a high risk of bias due to non-blinding, and most studies had a high or uncertain risk of bias in creating random assignment orders and concealing them. Bojungikgi-tang has an effect on the prevention and treatment of chemotherapy-induced leukopenia. The effect rate can be increased when administered after proper diagnosis, and the possibility of adverse reactions and side effects is lower than that of Granulocyte-Colony Stimulating Factor (G-CSF) injection. Bojungikgi-tang appears to be useful in the treatment and prevention of leukopenia caused by cytotoxic anticancer drugs. However, it is necessary to conduct high-quality clinical studies in the future, considering the possibility of local and language bias, heterogeneity of carcinoma and intervention, and the risk of bias.Registration: PROSPERO CRD4202341054.
化疗引起的白细胞减少症是细胞毒性抗癌药物的常见副作用。它可能使患者失去治疗机会，导致化疗或其他抗癌药物的延迟、减少或停止。两名研究人员检索了英文、中文、日文和韩文电子数据库，没有限制时间范围和语言，使用了“补骨脂”、“WBC”、“白细胞”和“中性粒细胞”等搜索词。在接受补骨脂汤治疗的接受化疗的患者的随机对照研究中，选择了报告与白细胞减少症相关结局的研究，并对入选论文进行了数据提取、偏倚风险评估和荟萃分析。共选择了 10 项研究，并进行了系统评价和荟萃分析。9 篇论文发表在中国，总参与者人数为 715 人。由于给这些患者服用补骨脂汤，化疗引起的白细胞减少症患者数量显著减少（OR：0.41，95%CI：0.27-0.61， = .0001， = 35%）。此外，与对照组相比，白细胞计数也显示出预防作用（MD：0.64，95%CI：0.46-0.83， < .00001， = 90%）。观察到明显的效果，尤其是在基于模式识别（如气虚）进行诊断后进行治疗时。（OR：0.32，95%CI：0.18-0.58， = .0002， = 0%）。然而，由于非盲法，所有研究都存在高度偏倚风险，大多数研究在制定随机分配顺序和隐藏这些顺序方面存在高或不确定的偏倚风险。补骨脂汤对预防和治疗化疗引起的白细胞减少症有作用。在适当诊断后进行治疗，可以提高有效率，而且不良反应和副作用的可能性低于粒细胞集落刺激因子（G-CSF）注射。补骨脂汤在治疗和预防细胞毒性抗癌药物引起的白细胞减少症方面可能有用。然而，考虑到局部和语言偏倚、癌种和干预措施的异质性以及偏倚风险的可能性，未来有必要开展高质量的临床研究。注册：PROSPERO CRD4202341054。
